Rapamycin Gets $2.5M For Anti Aging Drugs For Pets

San Antonio-based Rapaymyicn Holdings, which is developing anti-aging drugs for pets, said this week that it has raised $2.5M in a Series A funding round. The company said the funding came from San Antonio area angel investors. Rapamycin is developing anti-aging drugs based on research out of the University of Texas Health Science Center San Antonio. The startup is led by Randy Goldsmith. Rapamycin is initially focusing its drugs on companion pets. The company says it has now raised a total of $5M, and plans a Series B funding late this year or early next year.